Rxivist combines preprints from bioRxiv with data from Twitter to help you find the papers being discussed in your field. Currently indexing 65,152 bioRxiv papers from 288,686 authors.

Naturally occurring human genetic variants predicted to cause loss of function of protein-coding genes provide an in vivo model of human gene inactivation that complements cell and model organism knockout studies. Here we investigate the application of human loss-of-function variants to assess genes as candidate drug targets, with three key findings. First, even essential genes, where loss-of-function variants are not tolerated, can be highly successful as targets of inhibitory drugs. Second, in most genes, loss-of-function variants are sufficiently rare that genotype-based ascertainment of homozygous or compound heterozygous "knockout" humans will await sample sizes ~1,000 times those available at present. Third, automated variant annotation and filtering are powerful, but manual curation remains critical for removing artifacts and making biological inferences, and is a prerequisite for recall-by-genotype efforts. Our results provide a roadmap for human "knockout" studies and should guide interpretation of loss-of-function variants in drug development.

Download data

• Downloaded 3,399 times
• Download rankings, all-time:
  • Site-wide: 896 out of 65,152
  • In genomics: 232 out of 4,449
• Year to date:
  • Site-wide: 166 out of 65,152
• Since beginning of last month:
  • Site-wide: 1,320 out of 65,152

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide